The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC soft tissue and bone sarcoma group

被引:16
|
作者
Verweij, J
Nielsen, OS
Therasse, P
vanOosterom, AT
机构
[1] UNIV ROTTERDAM HOSP,NL-3075 EA ROTTERDAM,NETHERLANDS
[2] AARHUS UNIV HOSP,DEPT MED ONCOL,AARHUS,DENMARK
[3] EORTC DATA CTR,BRUSSELS,BELGIUM
[4] UNIV ANTWERP HOSP,DEPT MED ONCOL,EDEGEM,BELGIUM
关键词
quality control; chemotherapy; cancer;
D O I
10.1016/S0959-8049(97)00027-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to verify whether the introduction of a systemic therapy checklist in the performance of multinational multicentre studies improves the quality of data acquisition and recording. We retrospectively analysed the results obtained through the use of this checklist in a study of the EORTC Soft Tissue and Bone Sarcoma Group. During the clinical trial, data were recorded in the hospital record with optional use of a predesigned EORTC Systemic Therapy Checklist. After completion of the study, 11 centres were monitored for the use of this checklist. Monitors were highly experienced medical oncologists. Items checked included all aspects of patient eligibility, drug administration, biochemical and haematological values, variables related to toxicities of treatment and response parameters. Data of 183 cycles given to 51 patients were checked. A total of 8983 items were checked. 91% of the data was reported correctly, 1% was missing and 6% was reported on the case record from (CRF) but could not be retrieved in the hospital record file. Compared with data obtained before the introduction of the checklist (68% correct, 4% incorrect, 0.1% missing and 28% on CRF but not in hospital files), these results show marked improvement generally. In centres where no Systemic Therapy Checklist was used, 85.9% of data were correct 2.8% incorrect, 0.7% missing and 10.6% only on CRF, which compares unfavourably with those where the Systemic Checklist was completely used (97.7% correct, 0.7% incorrect, 1% missing, 0.6% only on CRF). In addition the time required for data checking largely decreased by the use of the checklist-without this, a median of 3.5 cycles could be checked per hour, whilst if the checklist was used, this number increased to 6.5 cycles per hour. The use of a Systemic Therapy Checklist as an integral part of the hospital file for data recording in multicentre multinational trials is highly recommended and leads to a major improvement in data quality. (C) 1997 Published by Elsevier Science Ltd.
引用
收藏
页码:1045 / 1049
页数:5
相关论文
共 50 条
  • [1] Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group
    Woll, PJ
    Judson, I
    Lee, SM
    Rodenhuis, S
    Nielsen, OS
    Buesa, JM
    Lorigan, PC
    Leyvraz, S
    Hermans, C
    van Glabbeke, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) : 410 - 412
  • [2] Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group
    Schlemmer, M.
    Reichardt, P.
    Verweij, J.
    Hartmann, J. T.
    Judson, I.
    Thyss, A.
    Hogendoorn, P. C. W.
    Marreaud, S.
    Van Glabbeke, M.
    Blay, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (16) : 2433 - 2436
  • [3] Effect of high-dose ifosfamide in advanced soft tissue sarcomas.: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Nielsen, OS
    Judson, I
    van Hoesel, Q
    le Cesne, A
    Keizer, HJ
    Blay, JY
    van Oosterom, A
    Radford, JA
    Svancárová, L
    Krzemienlecki, K
    Hermans, C
    van Glabbeke, M
    Oosterhuis, JW
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 61 - 67
  • [4] CYVADIC IN ADVANCED SOFT-TISSUE SARCOMA - A RANDOMIZED STUDY COMPARING 2 SCHEDULES - A STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    PINEDO, HM
    BRAMWELL, VHC
    MOURIDSEN, HT
    SOMERS, R
    VENDRIK, CPJ
    SANTORO, A
    BUESA, J
    WAGENER, T
    VANOOSTEROM, AT
    VANUNNIK, JAM
    SYLVESTER, R
    DEPAUW, M
    THOMAS, D
    BONADONNA, G
    CANCER, 1984, 53 (09) : 1825 - 1832
  • [5] Exatecan in pretreated adult patients with advanced soft tissue sarcoma:: Results of a phase II -: Study of the EORTC Soft Tissue and Bone Sarcoma Group
    Reichardt, P.
    Nielsen, O. S.
    Bauer, S.
    Hartmann, J. T.
    Schoffski, P.
    Christensen, T. B.
    Pink, D.
    Daugaard, S.
    Marreaud, S.
    van Glabbeke, M.
    Blay, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (06) : 1017 - 1022
  • [6] PHASE-II STUDY OF MITOZOLOMIDE IN ADVANCED SOFT-TISSUE SARCOMA OF ADULTS - THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    SOMERS, R
    SANTORO, A
    VERWEIJ, J
    LUCAS, P
    ROUESSE, J
    KOK, T
    CASALI, A
    SEYNAEVE, C
    THOMAS, D
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) : 855 - 857
  • [7] VP-16 IN ADVANCED SOFT-TISSUE SARCOMA - A PHASE-II STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    DOMBERNOWSKY, P
    BUESA, J
    PINEDO, HM
    SANTORO, A
    MOURIDSEN, H
    SOMERS, R
    BRAMWELL, V
    ONSRUD, M
    ROUESSE, J
    THOMAS, D
    SYLVESTER, R
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (05): : 579 - 580
  • [8] Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials
    Younger, Eugenie
    Litiere, Saskia
    Le Cesne, Axel
    Mir, Olivier
    Gelderblom, Hans
    Italiano, Antoine
    Marreaud, Sandrine
    Jones, Robin Lewis
    Gronchi, Alessandro
    van der Graaf, Winette T. A.
    ONCOLOGIST, 2018, 23 (10): : 1250 - 1259
  • [9] OUTCOME OF FIRST-LINE TREATMENT OF ELDERLY ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS: A POOLED ANALYSIS OF ELEVEN EORTC SOFT TISSUE AND BONE SARCOMA GROUP TRIALS
    van der Graaf, W. T. A.
    Le Cesne, A.
    Mir, O.
    Gelderblom, H.
    Italiano, A.
    Marreaud, S.
    Judson, I.
    Litiere, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Gemcitabine in advanced adult soft-tissue sarcomas.: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Svancárová, L
    Blay, JY
    Judson, IR
    van Hoesel, QGCM
    van Oosterom, AT
    le Cesne, A
    Keizer, HJ
    Hermans, C
    van Glabbeke, M
    Verweij, J
    Hogendoorn, PCW
    Nielsen, OS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) : 556 - 559